Drugs / ICP-192
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04565275 | Feb 2021 → Nov 2023 | cholangiocarcinoma, urothelial carcinoma | Beijing InnoCare Pharma Tech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03758664 | Dec 2018 → Dec 2024 | cancer | Beijing InnoCare Pharma Tech Co., Ltd. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05678270 | Nov 2022 → May 2026 overdue | intrahepatic cholangiocarcinoma | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05372120 | Dec 2021 → Dec 2023 | neoplastic disease or syndrome | Beijing InnoCare Pharma Tech Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04492293 | May 2020 → Dec 2024 | urinary bladder cancer | Beijing InnoCare Pharma Tech Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-01-25 | Beijing InnoCare Pharma Tech Co., Ltd. | Results 诺诚健华Gunagratinib最新临床数据在2023年美国临床肿瘤学会胃肠癌研讨会（ASCO GI）发布 innocarepharma.com ↗
截至2022年9月5日，研究共入组18名胆管癌患者，平均年龄52岁，44.4%为男性，每天一次口服20 毫克gunagratinib。 |
| 2022-06-06 | Beijing InnoCare Pharma Tech Co., Ltd. | Results 诺诚健华多项肿瘤管线最新数据在2022年美国临床肿瘤学会（ASCO）年会上公布 innocarepharma.com ↗
在具有FGF/FGFR基因异常（包括FGF扩增和FGFR突变）且至少完成一次肿瘤评估的9例头颈癌患者中，总缓解率（ORR）为33.3%，疾病控制率（DCR）为66.7%。 |
| 2021-06-09 | Beijing InnoCare Pharma Tech Co., Ltd. | Regulatory 诺诚健华泛FGFR抑制剂gunagratinib治疗胆管癌获美国FDA孤儿药资格认定 innocarepharma.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-01-25 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华Gunagratinib最新临床数据在2023年美国临床肿瘤学会胃肠癌研讨会（ASCO GI）发布 innocarepharma.com ↗ |
| 2022-06-06 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华多项肿瘤管线最新数据在2022年美国临床肿瘤学会（ASCO）年会上公布 innocarepharma.com ↗ |
| 2021-06-09 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华泛FGFR抑制剂gunagratinib治疗胆管癌获美国FDA孤儿药资格认定 innocarepharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-192 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05678270 ↗ |
| Route | Oral | “It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression” NCT05372120 ↗ |